Weissen Signs MOU with Catholic Kwandong University International St. Mary's Hospital

AI medtech specialist Weixen announced on the 11th that it signed a business agreement (MOU) with the Catholic Kwandong University International St. Mary's Hospital on the 10th for global medical business and joint research cooperation.

Through this agreement, the two organizations agreed to establish a practical cooperative system for the globalization of K-Medical. Key areas of collaboration include exchanges and collaborations related to overseas expansion and global expansion, the development of medical AI products and the joint development of projects for clinical application in domestic and international medical institutions, and the development of joint research projects based on AI technology. Through this, the goal is to establish a continuous collaboration model across all areas of clinical practice, research, and business.

International St. Mary's Hospital is expanding its medical cooperation network in CIS countries like Uzbekistan and Kazakhstan, as well as in Asian regions like Mongolia and Indonesia. Meanwhile, Weisen has been strengthening its global competitiveness in the field of AI endoscopy in Southeast Asia and the Middle East. The industry sees this agreement as a new synergy model for the globalization of Korean healthcare through collaboration between hospitals and companies.

“This agreement is not limited to the domestic market, but is a starting point for building an international partnership,” said Father Koh Dong-hyun, president and director of Catholic Kwandong University Medical Center. “We expect that together with Weixen, we will be able to discover new opportunities in the global healthcare market and advance the hospital’s internationalization.”

“Collaboration with medical institutions that best understand clinical practice is essential to securing technological reliability for global expansion,” said Weissen CEO Kim Kyung-nam. “This agreement will lay the foundation for our medical AI solutions to enter the global market more quickly and present a competitive K-Medical model overseas as well.”


  • See more related articles